Chemiluminescence Immunoassay Market Report 2026

Chemiluminescence Immunoassay Market Overview

• Chemiluminescence Immunoassay market size has reached to $14.85 billion in 2025 • Expected to grow to $22.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.5% • Growth Driver: Growing Prevalence Of Infectious Diseases Fueling The Growth Of The Market Due To Rising Antimicrobial Resistance • Market Trend: Advanced Immunoassay Analyzers Offers Quick Results And High Precision • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chemiluminescence Immunoassay Market?

Chemiluminescence immunoassay is a biochemical technique used to detect and quantify specific molecules, such as proteins, hormones, or pathogens, by combining antigen-antibody reactions with a chemiluminescent signal. In this method, light is emitted during a chemical reaction and measured to indicate the presence and concentration of the target analyte. It helps to provide highly sensitive, specific, and rapid diagnostic testing in clinical and research applications. The main types of products in chemiluminescence immunoassay are analyzers, kits, and reagents. Analyzers are specialized automated instruments designed to perform chemiluminescence immunoassay tests by detecting and measuring the light emitted during the chemical reaction. It encompasses sample types, such as blood, saliva, urine, and others, and utilizes various technologies, including chemiluminescence enzyme technology (CLEIA), electrochemiluminescence immunoassay (ECLI), and microparticle chemiluminescence immunoassay. It finds applications in therapeutic drug monitoring, oncology, cardiology, endocrinology, infectious disease, autoimmune disease, and others, and caters to diverse end users, including hospitals, pharmaceutical and biotechnology companies, clinical laboratories, and others.

What Is The Chemiluminescence Immunoassay Market Growth Forecast?

The chemiluminescence immunoassay market size is expected to see strong growth in the next few years. It will grow to $22.35 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing demand for early disease detection, rising adoption of personalized medicine diagnostics, expansion of decentralized testing models, growing integration of ai-assisted diagnostic interpretation, increasing investment in advanced clinical laboratory infrastructure. Major trends in the forecast period include increasing adoption of fully automated immunoassay analyzers, rising demand for high-sensitivity diagnostic kits, growing use of multiplex testing capabilities, expansion of rapid and point-of-care clia systems, enhanced focus on standardized reagent performance.

Global Chemiluminescence Immunoassay Market Segmentation

1) By Product Type: Analyzers, Kits, Reagents 2) By Sample Type: Blood, Saliva, Urine, Other Samples 3) By Technology: Chemiluminescence Enzyme Technology (CLEIA), Electrochemiluminescence Immunoassay (ECLI), Microparticle Chemiluminescence Immunoassay 4) By Application: Therapeutic Drug Monitoring, Oncology, Cardiology, Endocrinology, Infectious Disease, Autoimmune Disease, Other Applications 5) By End-User: Hospitals, Pharmaceutical And Biotechnology Companies, Clinical Laboratories, Other End-Users Subsegments: 1) By Analyzers: Fully Automated Analyzers, Semi Automated Analyzers, Portable Analyzers 2) By Kits: Detection Kits, Quantitative Kits, Qualitative Kits, Multiparameter Kits 3) By Reagents: Luminol Reagents, Isoluminol Reagents, Acridinium Ester Reagents, Other Reagents

What Is The Driver Of The Chemiluminescence Immunoassay Market?

The growing prevalence of infectious diseases is expected to propel the growth of the chemiluminescence immunoassay market going forward. Infectious diseases refer to illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that can spread directly or indirectly from one person to another. The prevalence of infectious diseases is increasing due to the rise in antimicrobial resistance, as it renders common treatments ineffective, allowing infections to persist and transmit. Chemiluminescence immunoassays aid in infectious disease diagnosis by delivering highly sensitive and specific biomarker detection, enabling early and accurate identification of pathogens. They reduce diagnostic delays by providing rapid and reliable results, improving patient management and treatment outcomes. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, tuberculosis (a contagious bacterial infection that primarily affects the lungs) cases in England rose to 4,850 in 2023, an increase of 10.7% from 4,380 cases in 2022. Therefore, the growing prevalence of infectious diseases is driving the growth of the chemiluminescence immunoassay industry.

Key Players In The Global Chemiluminescence Immunoassay Market

Major companies operating in the chemiluminescence immunoassay market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Shenzhen Mindray Bio-Medical Electronics Co. Ltd., QuidelOrtho Corporation, Sysmex Corporation, Bio-Rad Laboratories Inc., Revvity Inc., DiaSorin S.p.A., Tecan Group Ltd., Euroimmun AG, Randox Laboratories Ltd., Autobio Diagnostics Co. Ltd., Wondfo Biotech Co. Ltd., Fujirebio Diagnostics Inc., Trivitron Healthcare Pvt. Ltd., Getein Biotech Inc., Fapon Biotech Inc., Diazyme Laboratories Inc.

Global Chemiluminescence Immunoassay Market Trends and Insights

Major companies operating in the chemiluminescence immunoassay market are focusing on developing advanced products, such as advanced chemiluminescence immunoassay analyzers, to enhance test accuracy, increase throughput, and provide faster diagnostic results for a wide range of clinical applications. Chemiluminescence immunoassay analyzers are automated instruments that detect and measure light emitted during chemical reactions to accurately identify specific biomarkers in diagnostic tests. For instance, in July 2023, Fapon Biotech Inc., a China-based biotechnology company, launched the Shine i8000/9000, a chemiluminescence immunoassay analyzer. It is designed for medium to large laboratories, offering quick preliminary results within 10 minutes and high precision with a compact, stable, and user-friendly design. Its key features include a 360-degree large-span display, one-touch bulk loading for reaction cups, a dual-tube backup substrate system, and automatic reaction cup disposal to minimize contamination. Its fully automated workflow reduces manual intervention, while advanced algorithms enhance result consistency, making it ideal for high-volume diagnostic settings.

What Are Latest Mergers And Acquisitions In The Chemiluminescence Immunoassay Market?

In December 2023, Danaher Corporation, a US-based life sciences and diagnostics company, acquired Abcam Limited for approximately $5.7 billion. With this acquisition, Danaher aims to strengthen its Life Sciences segment by leveraging Abcam's validated antibodies, reagents, biomarkers, and assays to accelerate drug discovery and disease mapping, while allowing Abcam to operate independently. Abcam Limited is a UK-based life sciences company that offers chemiluminescence immunoassay kits and reagents.

Regional Outlook

North America was the largest region in the chemiluminescence immunoassay market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Chemiluminescence Immunoassay Market?

The chemiluminescence immunoassay market consists of revenues earned by entities by providing services such as high-sensitivity diagnostic testing, disease biomarker detection, clinical laboratory workflow optimization, and personalized healthcare diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The chemiluminescence immunoassay market also includes sales of immunoassay analyzers, control and calibration solutions, diagnostic consumables, and related accessories used for performing chemiluminescence-based diagnostic tests. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chemiluminescence Immunoassay Market Report 2026?

The chemiluminescence immunoassay market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chemiluminescence immunoassay industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.